ProCE Banner Activity

Long-term Solutions for Long-term Diseases: Using Long-Acting Injectable Antipsychotics in Practice

Podcast Episodes

Listen as Leslie Citrome, MD, MPH, and Adam Lowy, MD, share information on long-acting injectable antipsychotics ranging from pharmacokinetic properties to strategies on incorporating these agents into clinical practice.

Released: January 18, 2023

Expiration: January 17, 2024

No longer available for credit.

Share

Faculty

Leslie Citrome

Leslie Citrome, MD, MPH

Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Adam Lowy

Adam Lowy, MD

Staff Psychiatrist
Ellenhorn
Los Angeles, California

Supporters

Supported by an educational grant from

Otsuka America Pharmaceutical, Inc. and Lundbeck

Faculty Disclosure

Primary Author

Leslie Citrome, MD, MPH

Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Leslie Citrome, MD, MPH: consultant: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Mitsubishi-Tanabe Pharma, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva; speaker: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda; individual publicly traded stocks and stock options: Bristol-Myers Squibb, Johnson & Johnson, Lilly, Merck, Pfizer.

Adam Lowy, MD

Staff Psychiatrist
Ellenhorn
Los Angeles, California

Adam Lowy, MD: consultant/advisor/speaker: Alkermes, Axsome, Neurocrine.